Shulman Joseph of Rhythm Pharma sells $358,891 in shares

Rhythm Pharmaceuticals (RYTM) reported mixed Q2 2025 results, posting a wider-than-expected EPS loss of -$0.75 but significantly exceeding revenue forecasts with $48.5 million, marking a 29% sequential increase. This robust top-line performance and progress in its setmelanotide pipeline prompted multiple analysts, including H.C. Wainwright, TD Cowen, and Citizens JMP, to raise their price targets, indicating strong conviction despite the stock trading near its 52-week high and showing overbought technicals. Separately, CTO Joseph Shulman executed a pre-planned exercise and sale of 3,984 shares for $358,891.

Analysis

Rhythm Pharmaceuticals (RYTM) delivered a mixed financial report for the second quarter of 2025, characterized by robust top-line growth offset by a wider-than-expected net loss. The company's revenue of $48.5 million significantly surpassed analyst expectations of $43.75 million, representing a strong 29% quarter-over-quarter increase. However, the earnings per share (EPS) of -$0.75 missed the consensus estimate of -$0.67. Despite the earnings miss, the market and analyst community have focused on the impressive revenue performance and pipeline progress, including upcoming regulatory applications for setmelanotide. This positive sentiment is reflected in multiple price target increases from firms like H.C. Wainwright (to $100), TD Cowen (to $110), and Citizens JMP (to $135). The stock is currently trading near its 52-week high after a 112% surge over the past year, with technicals suggesting it is in overbought territory. The reported insider sale by the Chief Technical Officer, Joseph Shulman, of 3,984 shares for $358,891, is significantly mitigated by the fact it was conducted under a pre-scheduled Rule 10b5-1 plan and coincided with an option exercise for the same number of shares, a common practice for executives to cover costs.

Key Decisions for Investors

• Given the significant revenue beat and multiple upward revisions to analyst price targets, investors may interpret the current momentum as supportive of existing long positions, despite the recent EPS miss.
• With the stock trading near its 52-week high after a 112% annual gain and technical indicators showing overbought conditions, investors should be cautious of valuation risk and a potential for near-term price consolidation.
• Closely monitor the progress of regulatory filings for setmelanotide in the U.S. and EU this quarter, as these are critical near-term catalysts that are likely factored into the elevated price targets and valuation.
• The CTO's stock sale appears to be a routine, pre-planned transaction, but any future unplanned insider sales should be scrutinized as a more meaningful signal regarding management's outlook.